News

Sara Osborne, a fourth-year medical student and the lead author on the study, spoke with Dermatology Times on key findings and explain the need for further investigation.

Cutaneous and advanced stage melanomas present significant challenges during pregnancy, according to the posters.

A recent review found that disparities and barriers, such as income, age, and location, can impede patient access to necessary care.

Omar Noor, MD, and a patient with psoriasis share their unique perspectives on moderate to severe plaque psoriasis treatment with tildrakizumab.

Dermatologic emergency units are increasingly overwhelmed by rising patient volumes and reduced resources, but store-and-forward teledermatology offers an effective alternative.

Ethan Sims, MD, spoke with Dermatology Times on having positive conversations, cutting down on waste, and how to get involved in change.

Keep up with the latest headlines in dermatology from the past week, including high wait times to access dermatologic care in Quebec, the rise of digital dermatology, and more.

In case you missed it, this week had news about the 2024 Revolutionizing Alopecia Areata, Vitiligo, and Eczema Conference, the FDA-approved expanded use of tirbanibulin for actinic keratosis, FDA and EMA support of continuing MoonLake's phase 3 trial of sonelokimab for PsA, and more.

The program’s creator, Hubert Greenway, MD, has personally trained each of the fellowship’s 68 physicians in Mohs surgery.

Weekend treatment with cyclosporine may be beneficial for patients with moderate to severe psoriasis, according to a new study.

The organizations called for skin health to be considered a global public health priority in a recent side meeting at the World Health Assembly.

Researchers compared the examination's content outline with data on skin diseases in a recent study.

Although acne is common for most people to experience in their lifetime, it is important to individualize treatment and provide appropriate care when working with a diverse patient base.

Two new forms of Trichophyton mentagrophytes type VII and Trichophyton indotineae are emerging, according to a new report.

Terry Arnold, PA-C, shares a wide range of opportunities to take clinical experience to a different setting and tips to transition.

Review our coverage and expert interviews from the recent Society of Dermatology Physician Assistants' annual summer meeting.

A recent study found that AD not only affects mental health and QoL, but women’s sexual health and gestational desires as well.

Aubrie Jones, PA-C, MMS, and Laura Bush, DMSc, PA-C, DFAAPA, discuss the role of the SDPA in supporting the growth and journeys of PAs at all stages.

VYNE Therapeutics Inc. shared that top-line data from the trial is expected in the second half of 2024.

Today, June 13, is the 10th annual International Albinism Awareness Day.

LEO Pharma's Adbry, a single-dose autoinjector, is expected to become available to patients in the coming months.

Gottlieb reviews her lecture from the Society for Investigative Dermatology Annual Meeting.

To address the increased rates of skin cancer while keeping unique patient needs top of mind, there is a pressing need to increase options for treatment.

A recent review found that teledermatology could improve patient access, increase efficiency, and cut down on costly hospital admissions.

Ahead of the next 3 months of the year, Dermatology Times wants to know what conferences and meetings you plan to attend between July and September. Share your thoughts with us by June 26.

Conversely, there were higher levels of selenium and folic acid detected in patients with vitiligo versus otherwise healthy individuals.

The study found patients with vitiligo are at a lower risk of developing PD, but those with comorbid PD could face elevated mortality rates.

Researchers hypothesize that skin contact with e-cigarette fluids can trigger an inflammatory response.

Catch up on all clinical pearls from the 2024 Revolutionizing Alopecia Areata, Vitiligo, and Eczema Conference in Chicago, Illinois.

Jonathan Silverberg, MD, PhD, MPH, and Melinda Gooderham, MSc, MD, FRCPC, debated which patients are a contender for systemic therapy.